PHI with Acetylsalicylic acid allergy
How does this condition affect your private health insurance?
Acetylsalicylsäureallergie, or Aspirin-Exacerbated Respiratory Disease (AERD), is not a true IgE-mediated allergy but a pseudoallergic reaction to aspirin and other NSAIDs. It typically manifests as a triad of asthma, chronic rhinosinusitis with nasal polyps, and sensitivity to aspirin, often termed Samter's Triad. Symptoms, including bronchospasm, nasal congestion, and skin rashes (urticaria, angioedema), usually appear within minutes to hours of ingestion. In some individuals, severe anaphylactic-like reactions can occur. The underlying mechanism involves abnormal arachidonic acid metabolism and increased leukotriene production. Management focuses on strict avoidance of trigger drugs and, for some, aspirin desensitization.
PKV Risk Assessment
However, some specialized PHI providers may insure you with a surcharge of up to 5%.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Minutes to several hours, rarely up to a few days for severe reactions requiring sustained medical intervention.
Duration of Illness (Lifetime)
Lifelong sensitivity, requiring continuous avoidance of triggers. The underlying pseudoallergic predisposition persists indefinitely.
Cost of Treatment (Initial)
Low for mild reactions (e.g., antihistamines, corticosteroids), higher for severe reactions requiring emergency medical attention (e.g., hospital visit, epinephrine) ranging from hundreds to several thousands of dollars.
Cost of Treatment (Lifetime)
Primarily low for avoidance, but may include significant costs for managing associated conditions like asthma and nasal polyps (medications, surgeries). Aspirin desensitization, if pursued, is a significant initial cost.
Mortality Rate
Low, but possible in cases of severe anaphylaxis or acute respiratory distress if not promptly and effectively treated (estimated <1%).
Risk of Secondary Damages
Moderate, especially for individuals with Aspirin-Exacerbated Respiratory Disease (AERD), leading to chronic rhinosinusitis, recurrent nasal polyps, and difficult-to-control asthma. Psychological burden from constant vigilance for triggers can also occur.
Probability of Full Recovery
Very low for the underlying sensitivity; it is generally a lifelong condition. Symptomatic management and avoidance can achieve a symptom-free state, and desensitization can induce tolerance.
Underlying Disease Risk
High, particularly for Aspirin-Exacerbated Respiratory Disease (AERD), where it is often associated with pre-existing asthma (60-80%) and chronic rhinosinusitis with nasal polyps (90-100% in AERD patients).